Skip to content

Adult Spinal Muscular Atrophy (SMA) China Registry

Adult Patients With Spinal Muscular Atrophy in China: A Nationwide Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05618379
Enrollment
200
Registered
2022-11-16
Start date
2023-01-06
Completion date
2028-06-01
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscular Atrophy, Spinal

Brief summary

The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).

Interventions

None listed

Sponsors

Biogen
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Key Inclusion Criteria: -Genetically confirmed 5q-SMA. Key

Exclusion criteria

-Other types of SMA (non 5q-SMA). NOTE: Other protocol defined Inclusion/

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Characterized by Natural History of 5q-SMA Observed Among Adult Chinese ParticipantsUp to 60 MonthsThe natural history characteristics will include the categories of the evolution of the patient's condition over the time of data collection from the registry, to describe the natural history of the disease in a real-life situation.
Number of Participants Characterized by Utilization of Disease Modifying Therapies (DMTs) of 5q-SMA Observed Among Adult Chinese ParticipantsUp to 60 MonthsThe DMT utilization characteristics will include the categories of the evolution of the DMT treated patient's condition over the time of data collection from the registry, to describe the utilization of DMTs of adult SMA patients in a real-life situation.

Countries

China

Contacts

STUDY_DIRECTORMedical Director

Biogen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026